Bicycle Therapeutics plc
BCYC
$9.69
$0.060.62%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 35.28M | 36.90M | 39.57M | 41.61M | 26.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.28M | 36.90M | 39.57M | 41.61M | 26.98M |
| Cost of Revenue | 56.07M | 168.05M | 160.58M | 159.42M | 156.50M |
| Gross Profit | -17.09M | -131.15M | -121.00M | -117.81M | -129.52M |
| SG&A Expenses | 72.18M | 65.29M | 62.39M | 62.05M | 60.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 245.15M | 233.34M | 222.97M | 221.47M | 216.92M |
| Operating Income | -209.87M | -196.44M | -183.40M | -179.86M | -189.95M |
| Income Before Tax | -173.80M | -169.64M | -163.02M | -166.44M | -179.21M |
| Income Tax Expenses | -4.77M | -3.36M | 2.36M | 1.73M | 1.46M |
| Earnings from Continuing Operations | -169.03 | -166.28 | -165.37 | -168.16 | -180.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -169.03M | -166.28M | -165.37M | -168.16M | -180.66M |
| EBIT | -209.87M | -196.44M | -183.40M | -179.86M | -189.95M |
| EBITDA | -202.70M | -189.32M | -176.75M | -173.21M | -183.40M |
| EPS Basic | -2.88 | -3.28 | -3.81 | -4.45 | -5.13 |
| Normalized Basic EPS | -1.87 | -2.07 | -2.34 | -2.76 | -3.19 |
| EPS Diluted | -2.88 | -3.28 | -3.81 | -4.45 | -5.13 |
| Normalized Diluted EPS | -1.87 | -2.07 | -2.34 | -2.76 | -3.19 |
| Average Basic Shares Outstanding | 232.59M | 205.96M | 176.55M | 154.75M | 142.19M |
| Average Diluted Shares Outstanding | 232.59M | 205.96M | 176.55M | 154.75M | 142.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
